Login to Your Account



Qiagen's $130M Purchase of DxS a 13X Profit for Investors

By Nuala Moran


Wednesday, September 30, 2009
LONDON - There was a record return for all the investors in companion diagnostics pioneer DxS Ltd., when the company was acquired last week by Qiagen NV for a total of up to $130 million. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription